Clearbridge Strengthens Asian Liquid Biopsy Ties
This article was originally published in Clinica
Executive Summary
Clearbridge BioMedics, the Singapore-based developer of circulating tumor cell capture technology for liquid biopsies, has further strengthened its Asian distributor network. The company has enlisted BGI Shenzhen, the world's largest genome institute, to distribute its ClearCell FX1 system in China, including Hong Kong and Macao.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.